TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~≥10 chronic prescription medications On anticoagulants Diagnosis of CHF, AMI On narrow therapeutic index drugs E.g. valproic acid, phenytoin, lithium, digoxin History of transplant AND not admitted by transplant team~Exclusion Criteria:~Trauma patients Pediatric patients History of transplant and admitted to the transplant team Patients admitted from or discharged to a SNF or hospice Non-English speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: NO_INTERVENTION): No extra post-discharge pharmacist counseling is explicitly provided to patients, although some patients may receive it depending on their care setting
- Post-discharge pharmacist counseling (Type: EXPERIMENTAL): Patients will receive post-discharge telephonic pharmacist counseling at around 72 hours after hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of: - Epithelial ovarian carcinoma - Fallopian tube carcinoma - Primary serous peritoneal carcinoma~* Radiologically documented measurable disease according to RECIST criteria assessed by Computerised Tomography (CT) or Magnetic Resonance Imaging MRI) or radiologically documented non-measurable (but evaluable) disease.~* Advanced disease not amenable to curative surgery or radiotherapy at the time of study entry with evidence of disease recurrence or progression at least 6 months following treatment cessation of first-line platinum- containing therapy~Exclusion Criteria:~* Clinical evidence of central nervous system (CNS) metastases~* Non-epithelial ovarian cancer, including malignant mixed Mullerian tumours and mucinous carcinoma of the peritoneum~* Tumour of borderline malignancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZD4054 + paclitaxel + carboplatin (Type: EXPERIMENTAL): ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
- Placebo + paclitaxel + carboplatin (Type: PLACEBO_COMPARATOR): Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Registry to Collect Patient Outcome Date for the BIOMET® Stimulator Systems

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject has agreed to undergo electrical stimulation therapy as prescribed by their physician.~2. Subject has agreed to return to the physician for their physician required follow up visits.~3. Subject will undergo treatment with Biomet's BHS, OrthoPak or SpinalPak devices.~4. Subject has agreed to complete QoL questionnaires prior to starting treatment and at the follow up visit when the physician has determined the subject to be either healed or failed.~Exclusion Criteria:~1. Any subject not willing to comply with the physician prescribed treatment program and follow up visit schedule.~2. Any subject not willing to complete the QoL questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stimulation Group (Type: None): All patients will receive either the Biomet® EBI Bone Healing System, Biomet OrthoPak® Non-invasive Bone Growth Stimulator System or Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator Systems.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ridge Preservation With Moldable Beta-tricalcium Phosphate Bone Substitute on Non-containable Non-Molar Extraction Sites

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adequate restorative space for a dental implant restoration, if the subject decides previous to study participation that they would like an implant. Note, agreement to implant placement is not a requirement of the study~* minimum of 10-mm vertical bone without impinging on adjacent vital structures (Maxillary sinus, neurovascular bundles)~* single-rooted tooth to be extracted~* American Society of Anesthesiologists (ASA) Physical Status Classification I or II~* age \>18 years old~* subjects who had \>50% of height on any portion on the buccal wall of dehiscence and/or fenestration of the extraction socket following extraction will be included from this study~* adjacent teeth to extraction site will be present during healing period~* willingly sign informed consent and authorization.~Exclusion Criteria:~* do not meet any inclusion criteria~* pregnancy or nursing woman~* subjects with active systemic or localized infection (exclude chronic periodontitis)~* subjects with a history of any medical conditions that contraindicated or weighed against dental implant placement such as history of bisphosphonate drug use, chemotherapeutic or immunosuppressive agents, autoimmune disease, or poorly controlled diabetes (HBA1c\>7%)~* subjects with smoking habit (more than 10 cigarettes per day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device treatment (Type: EXPERIMENTAL): easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Diabetes and Glucose Control During Rehabilitation After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inpatient rehabilitation for acute stroke~Exclusion Criteria:~* Medical records unavailable

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Undergone diagnostic coronary angiography~* Evidence of coronary pathology that requires further imaging to guide treatment~Exclusion criteria:~Significant renal insufficiency

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: None): Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~3.1.1 Patients must be at least 3 years of age and ≤ 18 years of age at the time of study enrollment.~3.1.2 Patients must have clinical findings and neuroradiographic findings consistent with diffuse intrinsic pontine glioma. Histologic confirmation of diagnosis is not required for diffuse intrinsic pontine gliomas. A copy of the MRI must be submitted for verification of eligibility.~3.1.3 Patients must have received conventional radiation therapy of total radiation dosage ranging from 5400 to 6000 cGy administered in fractions of 150 to 200 cGy over 6 weeks.~3.1.4 Treatment must start 14 to 28 days after completion of conventional radiation~3.1.5 Patients receiving systemic corticosteroid therapy must be on a tapering or stable low (2 mg twice daily) dose of dexamethasone two weeks after conventional radiation.~3.1.6 Patients life expectancy must be greater or equal to 8 weeks.~3.1.7 Patients must have a performance status (Lansky or Karnofsky) ≥ 50.~3.1.8 Platelet count ≥ 100,000/ mm3.~3.1.9 Hemoglobin ≥ 10 g/dL.~3.1.10 Creatinine ≤ 2.0 mg/dL.~3.1.11 Serum bilirubin ≤ 5.0 mg/dL.~3.1.12 If female, patients of childbearing potential must have a negative serum β-hCG pregnancy test.~3.1.13 Both male and female patients must agree to use hormonal or barrier birth control with spermicidal gel to avoid pregnancy during the study.~3.1.14 The patient and/or their guardian must have the ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria~3.2.1 Prior therapy for diffuse intrinsic pontine glioma, aside from surgery, conventional radiation, and temozolomide.~3.2.2 Use of any experimental drug for any reason within the 60 days prior to treatment.~3.2.3 Active infection requiring treatment.~3.2.4 Known medical condition that, in the opinion of the Investigator, would compromise the patient's ability to participate in the study. This would include chronic active hepatitis infection, known immunosuppressive disease or concurrent neurodegenerative disease.~3.2.5 Known allergy or hypersensitivity to any of the components of the vaccine treatment, including GM-CSF, yeast derived products, or a history of anaphylactic reactions to shellfish proteins.~3.2.6 Pregnant women and women who are breast-feeding.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Rindopepimut (EGFRvIII Vaccine, CDX-110) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 50-89 (inclusive) at screening~* Diagnosed as having Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) or Mild probable AD according to workgroups of the Diagnostic Guidelines of the National Institute on Aging and Alzheimer's Association (NIA-AA)~* Mini-Mental State Examination (MMSE) score 20-30 inclusive at screening~* Montreal Cognitive Assessment score (MoCA) \< 26 at screening~* Clinical Dementia Rating global score 0.5 or 1 with memory score of \> 0.5 at screening~* Positive CSF AD biomarker signature~* A brain MRI scan within 6 months of screening consistent with a diagnosis of Alzheimer's disease~* Participants must have a study partner who has frequent interaction with them (approximately \>3-4 times per week), will be present for all clinic visits, and can assist in compliance with study procedures.~Key Exclusion Criteria:~* • Significant neurodegenerative diseases and causes of dementia, other than AD, including Parkinson's disease and Huntington's disease, vascular dementia, CJD (Creutzfeldt-Jakob disease), LBD (Lewy Body dementia), PSP (Progressive Supranuclear Palsy), AIDS (Acquired Immunodeficiency Syndrome), or NPH (normal pressure hydrocephalus)~* Meeting Diagnostic Criteria for Possible AD according to workgroups of the Diagnostic Guidelines of the NIA-AA~* Hepatic impairment defined as Child-Pugh class A or more severe liver impairment~* History of moderate or severe skin reactions to medications or current moderate or severe disease of the skin and subcutaneous tissues~* History of a major depressive episode within the past 6 months of screening~* History of diagnosis of schizophrenia~* History of uncontrolled bipolar disorder within past five years of screening~* History of seizures within past two years of screening~* Contraindication to lumbar puncture and MRI~* Participation in another clinical trial for an investigational agent and having taken at least one dose of study drug, unless confirmed as having been on placebo, within 90 days prior to the baseline visit. The end of a previous investigational trial is defined as the date of the last dose of an investigational agent.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- 600 mg (Type: EXPERIMENTAL): First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID
- 300 mg (Type: EXPERIMENTAL): First 4 weeks 150 mg BID, week 5-24 300 mg BID
- 150 mg (Type: EXPERIMENTAL): 24 weeks on 150 mg BID
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 50 years and ≤ 75 years~* Life expectancy \>10 years~* Localized prostatic adenocarcinoma and histologically proven~* Intermediate risk cancer(T2b or PSA between 10 and 20 or Gleason = 7(3+4) according to Amico criteria~* Metastasis or pelvic pathologic ganglion (≥ 10 mm) absence~* OMS \< 2~* No previous treatment by radiotherapy and/or curietherapy~* Hormonotherapy authorized before and during the study~* Rectal or uretero-vesical pathology~* Signed informed consent~* Social security system affiliation~* Individual deprived of liberty or placed under the authority of a tutor.~* No anesthesia contraindication~Exclusion Criteria:~* Adenocarcinoma not histologically proven~* Metastases presence~* Pathological nodes presence(≥ 10 mm)~* Prior prostate endoscopic resection~* history of other malignancy except for appropriately treated superficial basal cell skin cancer~* Medical contraindications to anesthesia~* Patients with uncontrolled psychiatric disease or medical disease incompatible with the protocol~* Impossibility to respect the medical follow-up of the protocol for geographical, social or psychic reasons

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Outcomes in Vascular Access

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age 18 years or more. All patients referred to the vascular access clinic. Able to give valid informed consent.~Exclusion criteria Unable to give informed consent. \<18 years old Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Episiotomy on Maternal and Fetal Outcomes (EPITRIAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women in labor, or women scheduled for induction of labor, or women attending for a routine follow-up examination during third trimester of pregnancy.~* First vaginal delivery~* Singleton pregnancy above 34 gestational weeks~* Vertex presentation~* Women who are able to understand and sign the informed consent forms.~Exclusion Criteria:~Absolute contraindications for vaginal delivery (e.g. placenta previa, fetal macrosomia above 4.5 kg, genital herpes)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- No episiotomy (Type: EXPERIMENTAL): Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
- Selective episiotomy (Type: NO_INTERVENTION): The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older with a diagnosis of T2DM with a scheduled office visit with primary care provider within the next 4 weeks~2. Last 2 HbA1c values between 7.5 - 10% measured in the last 12 months~3. Treated with non-insulin therapies or therapeutic lifestyle changes~4. Never worn professional CGM or have not worn in last 12 months~5. Willing to perform requirements needed for professional CGM~Exclusion Criteria:~1. Current or previous treatment with any insulin within 3 months at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3-Month iPro2 Professional CGM (Type: EXPERIMENTAL): Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
- 6-Month iPro2 Professional CGM (Type: EXPERIMENTAL): Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sedation Strategies for Therapeutic Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for flexible therapeutic bronchoscopy~* Adult patients aged 18 to 65 years~* American Society of Anesthesiologists (ASA) Physical Status Classification I-II~* BMI 18.5-25kg/m2~* Subjects provide informed consent~Exclusion Criteria:~* Severe airway obstruction~* Coagulation disorder~* Repeat bronchoscopy (more than 3 times)~* Severe liver and renal dysfunction~* Cardiovascular and cerebrovascular diseases~* Pregnancy~* Chronic opioid user~* Drug abusers or addicts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group DR (Type: EXPERIMENTAL): Patients sedated with dexmedetomidine and remifentanil.
- Group LMA (Type: EXPERIMENTAL): General anesthesia was applied using laryngeal mask.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Study of Barrett's Esophagus: What Are the Factors of Progression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Sex: Male and female~* Age: 18-80 years~* Confirmed BE.~Exclusion Criteria:~* Columnar mucosa in the distal esophagus but no intestinal metaplasia on biopsy.~* Patients with BE who have undergone endoscopic ablation therapy or enrolled in chemoprevention trials. Since this is a natural history study, patients enrolled in intervention trials (e.g. those undergoing endoscopic ablation of their BE) will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: None): Patients with confirmed Barrett's Esophagus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues